Search

Your search keyword '"Alagal, Reham I."' showing total 31 results
Start Over Author "Alagal, Reham I."
31 results on '"Alagal, Reham I."'

22. The protection afforded by Berberine against chemotherapy‐mediated nephropathy in rats involves regulation of the antioxidant axis.

Author

Alagal, Reham I., AlFaris, Nora A., Alshammari, Ghedeir M., ALTamimi, Jozaa Z., AlMousa, Lujain A., and Yahya, Mohammed Abdo

Subjects
*BERBERINE, *REACTIVE oxygen species, *KIDNEY diseases, *SUPEROXIDE dismutase, *NUCLEAR factor E2 related factor, *RATS
Abstract

Doxorubicin (DOX) treatment in cancer patients leads to nephrotoxicity. The nephroprotective effect of Berberine (BBR), a herbal ingredient, is well documented as antioxidant and activation of the Nrf2 signalling. This study aimed to investigate if Nrf2 is a major protective mechanism of BBR in DOX animal models. Rats were divided as (n = 6 each): Control, BBR (100 mg/kg, orally), DOX (15 mg/kg, orally), BBR + DOX, and BBR + DOX + brusatol (0.2 mg/kg, i.p./twice per week) (an Nrf2 inhibitor). DOX was given as a single dose (day 10), whereas BBR was administered for 3 weeks on a daily basis. BBR reduced tubular degeneration and improved renal markers in DOX‐treated rats. It also reduced renal nuclear levels of NF‐κB p65, total reactive oxygen species (ROS), lipid peroxides, interleukin‐6 (IL‐6), and tumour necrosis factor‐α (TNF‐α), as well as mRNA levels of Bax and cleaved caspase‐3. However, BBR stimulated glutathione (GSH) and superoxide dismutase (SOD) levels, the transcription of Bcl2, and the mRNA, total cytoplasmic, and nuclear levels of Nrf2 with no effect on the cytoplasmic keap1 levels. All these effects disappeared by brusatol. In conclusion, BBR prevents DOX‐induced renal damage by activating Nrf2. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

23. Ellagic acid protects against non-alcoholic fatty liver disease in streptozotocindiabetic rats by activating AMPK.

Author

AL Tamimi, Jozaa Z., Alshammari, Ghedeir M., AlFaris, Nora A., Alagal, Reham I., Aljabryn, Dalal H., Albekairi, Norah A., Alkhateeb, Mahmoud Ahmad, and Yahya, Mohammed Abdo

Subjects
NON-alcoholic fatty liver disease, AMP-activated protein kinases, ELLAGIC acid, RAT diseases, TYPE 1 diabetes
Abstract

Context: Ellagic acid (EA) is used in traditional medicine to treated hyperlipidaemia. Objective: This study examined if AMPK mediates the anti-steatotic effect of ellagic acid (EA) in streptozotocin (STZ)-induced type 1 diabetes mellitus in rats. Materials and methods: Adult male Wistar rats (130 ± 10 g) were divided into 6 groups (n=8 rats/group) as control, controlþEA, controlþEAþCC an AMPK inhibitor), T1DM, T1DMþEA, and T1DMþEAþCC. The treatments with EA (50 mg/kg/orally) and CC (200 ng/rat/i.p.) were given the desired groups for 12 weeks, daily. Results: In T1DM-rats, EA reduced fasting glucose levels (44.8%), increased fasting insulin levels (92.8%), prevented hepatic lipid accumulation, and decreased hepatic and serum levels of total triglycerides (54% & 61%), cholesterol (57% & 48%), and free fatty acids (40% & 37%). It also reduced hepatic levels of ROS (62%), MDA (52%), TNF-a (62%), and IL-6 (57.2%) and the nuclear activity of NF-jB p65 (54%) but increased the nuclear activity of Nrf-2 (4-fold) and levels of GSH (107%) and SOD (87%). Besides, EA reduced downregulated SREBP1 (35%), SREBP2 (34%), ACC-1 (36%), FAS (38%), and HMG-CoAR (49%) but stimulated mRNA levels of PPARa (1.7-fold) and CPT1a (1.8-fold), CPT1b (2.9-fold), and p-AMPK (4-fold). All these events were prevented by the co-administration of CC. Discussion and conclusions: These findings encourage the use of EA to treat hepatic disorders, and non-alcoholic fatty liver disease (NAFLD). Further in vivo and in vitro studies are needed to validate its potential in clinical medicine. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

30. Rumex nervosuscould alleviate streptozotocin-induced diabetic nephropathy in rats by activating Nrf2 signaling

Author

AlMousa, Lujain A, AlFaris, Nora A, Alshammari, Ghedeir M, Alsayadi, Muneer M, ALTamimi, Jozaa Z, Alagal, Reham I, and Yahya, Mohammed Abdo

Abstract

This study tested the protective effect of Rumex nervous (R. nervosus)methanol extract against streptozotocin (STZ)-mediated type 1 diabetes mellitus (T1DM)-induced nephropathy in rats and examined if this protection involves activating the nuclear factor erythroid 2 related factor-2 (Nrf2). Rats were divided into control, R. nervous(300 mg), STZ (T1DM), STZ + R. nervosus(100, 200, or 300 mg/kg), and STZ + R. nervosus(300 mg/kg) + brusatol (an Nrf2 inhibitor). With no effect on fasting glucose and insulin levels, R. nervosusmethanol extract preserved kidney histological structure and alterations kidney function markers (e.g. albumin, creatinine, and urine volume) in the STZ-diabetic rats. R. nervosusalso reduced levels of reactive oxygen species (ROS), malondialdehyde (MDA), tumor necrosis factor-α (TNF-α), and interleukine-6 (IL-6), nuclear levels of the nuclear factor kappa beta (NF-κB), and mRNA of caspase-3 and Bax in the kidneys of these diabetic rats. Concomitantly, it stimulated renal mRNA levels of Bcl2 and Nrf2, cytoplasmic and nuclear levels of Nrf2, and levels of glutathione (GSH), catalase (CAT), and superoxide dismutase (SOD). All these effects were dose-dependent, with the maximum effect seen with the 300 mg/kg dose, all prevented by brusatol. Also, these effects occurred without any alteration in the transcription of the Kelch-like ECH-associated protein 1 (keap-1). Similar effects on levels of GSH, SOD, CAT, and NF-κB, as well as expression of Nrf2, were also observed in the kidney of control + R. nervous-treated rats. In conclusion, R. nervosusprevents diabetic nephropathy in rats by upregulating and activating Nrf2.

Published
2022
Full Text
View/download PDF

31. Ellagic acid protects against non-alcoholic fatty liver disease in streptozotocin-diabetic rats by activating AMPK.

Author

ALTamimi JZ, Alshammari GM, AlFaris NA, Alagal RI, Aljabryn DH, Albekairi NA, Alkhateeb MA, and Yahya MA

Subjects
AMP-Activated Protein Kinases metabolism, Animals, Blood Glucose drug effects, Diabetes Mellitus, Experimental complications, Diabetes Mellitus, Type 1 complications, Insulin blood, Male, Non-alcoholic Fatty Liver Disease etiology, Rats, Rats, Wistar, Streptozocin, Diabetes Mellitus, Experimental drug therapy, Diabetes Mellitus, Type 1 drug therapy, Ellagic Acid pharmacology, Non-alcoholic Fatty Liver Disease prevention & control
Abstract

Context: Ellagic acid (EA) is used in traditional medicine to treated hyperlipidaemia., Objective: This study examined if AMPK mediates the anti-steatotic effect of ellagic acid (EA) in streptozotocin (STZ)-induced type 1 diabetes mellitus in rats., Materials and Methods: Adult male Wistar rats (130 ± 10 g) were divided into 6 groups ( n  = 8 rats/group) as control, control + EA, control + EA + CC an AMPK inhibitor), T1DM, T1DM + EA, and T1DM + EA + CC. The treatments with EA (50 mg/kg/orally) and CC (200 ng/rat/i.p.) were given the desired groups for 12 weeks, daily., Results: In T1DM-rats, EA reduced fasting glucose levels (44.8%), increased fasting insulin levels (92.8%), prevented hepatic lipid accumulation, and decreased hepatic and serum levels of total triglycerides (54% & 61%), cholesterol (57% & 48%), and free fatty acids (40% & 37%). It also reduced hepatic levels of ROS (62%), MDA (52%), TNF-α (62%), and IL-6 (57.2%) and the nuclear activity of NF-κB p65 (54%) but increased the nuclear activity of Nrf-2 (4-fold) and levels of GSH (107%) and SOD (87%). Besides, EA reduced downregulated SREBP1 (35%), SREBP2 (34%), ACC-1 (36%), FAS (38%), and HMG-CoAR (49%) but stimulated mRNA levels of PPARα (1.7-fold) and CPT1a (1.8-fold), CPT1b (2.9-fold), and p-AMPK (4-fold). All these events were prevented by the co-administration of CC., Discussion and Conclusions: These findings encourage the use of EA to treat hepatic disorders, and non-alcoholic fatty liver disease (NAFLD). Further in vivo and in vitro studies are needed to validate its potential in clinical medicine.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results